Система антиоксидантной защиты слюны при немелкоклеточном раке легкого

The purpose of the study was to study parameters of the antioxidant protection system in saliva for non-small cell lung cancer. In the case-control study, included 683 volunteers, which were divided into 3 groups: primary (lung cancer patients, n = 290), comparison group (patients with nonmalignant pulmonary pathologies, n = 178) and control (conditionally healthy individuals, n = 215). Biochemical examination of saliva, histological verification of the diagnosis were carried out for all participants. The parameters of the antioxidant defense was determined spectrophotometrically. Intergroup differences were estimated by a nonparametric criterion. Saliva of lung cancer patients was characterized by imbalance in the antioxidant defense. It is shown that the activity of the enzymes of the first link of antioxidant protection (catalase, SOD) was significantly reduced (p ˂ 0.0001), whereas activity of salivary peroxidases increase (p = 0.0037). The parameters of non-enzymatic protection varied in opposite directions: the level of uric acid in lung pathologies decreases (p = 0.0399), whereas albumin concentration increased, under these conditions, it begins to exhibit prooxidant properties. Differences between adenocarcinoma and squamous cell lung cancer have been found in terms of the mode of the dynamics of antioxidant protection parameters. Probably, against the background of squamous cell lung cancer, an enzymatic link (catalase, SOD) contributes to the antioxidant protection system, whereas against adenocarcinoma - nonenzymatic (uric acid, albumin).Цель исследования – изучение показателей системы антиоксидантной защиты в слюне при немелкоклеточном раке легкого. В исследовании «случай – контроль» приняли участие 683 добровольца, которые были разделены на 3 группы: основную (рак легкого, n = 290), группу сравнения (незлокачественные легочные патологии, n = 178) и контрольную (условно здоровые, n = 215). Всем участникам было проведено биохимическое исследование слюны, гистологическая верификация диагноза. Параметры антиоксидантной защиты определены спектрофотометрически. Межгрупповые различия оценены непараметрическим критерием. В образцах слюны пациентов с раком легких отмечено нарушение баланса антиоксидантной защиты в слюне. Активность ферментов первого звена антиоксидантной защиты (каталаза, SOD) существенно снижается (р ˂ 0.0001), тогда как активность пероксидаз слюны растет (р = 0.0037). Показатели неферментативной защиты меняются разнонаправленно: уровень мочевой кислоты при патологиях легких снижается (р = 0.0399), тогда как концентрация альбумина растет; в данных условиях он начинает проявлять прооксидантные свойства. Выявлены различия между аденокарциномой и плоскоклеточным раком легкого по характеру динамики показателей антиоксидантной защиты. Вероятно, на фоне плоскоклеточного рака легких больший вклад в систему антиоксидантной защиты вносит ферментативное звено (каталаза, SOD), тогда как на фоне аденокарциномы – неферментативное (мочевая кислота, альбумин)

Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC).

e16577Background: Majority of patients (pts) with ccRCC at first line (1L) treatment are classified in the IR subgroup according to International Metastatic Renal Cell Carcinoma Database Consortium..

F-036EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS ARE LINKED TO SKIP N2 LYMPH NODE METASTASIS IN RESECTED NON-SMALL CELL LUNG CANCER ADENOCARCINOMAS

n/

Role of multiparametric magnetic resonance imaging in early detection of prostate cancer.

UNLABELLED: Most prostate cancers (PC) are currently found on the basis of an elevated PSA, although this biomarker has only moderate accuracy. Histological confirmation is traditionally obtained by random transrectal ultrasound guided biopsy, but this approach may underestimate PC. It is generally accepted that a clinically significant PC requires treatment, but in case of an non-significant PC, deferment of treatment and inclusion in an active surveillance program is a valid option. The implementation of multiparametric magnetic resonance imaging (mpMRI) into a screening program may reduce the risk of overdetection of non-significant PC and improve the early detection of clinically significant PC. A mpMRI consists of T2-weighted images supplemented with diffusion-weighted imaging, dynamic contrast enhanced imaging, and/or magnetic resonance spectroscopic imaging and is preferably performed and reported according to the uniform quality standards of the Prostate Imaging Reporting and Data System (PIRADS). International guidelines currently recommend mpMRI in patients with persistently rising PSA and previous negative biopsies, but mpMRI may also be used before first biopsy to improve the biopsy yield by targeting suspicious lesions or to assist in the selection of low-risk patients in whom consideration could be given for surveillance. TEACHING POINTS: ? MpMRI may be used to detect or exclude significant prostate cancer. ? MpMRI can guide targeted rebiopsy in patients with previous negative biopsies. ? In patients with negative mpMRI consideration could be given for surveillance. ? MpMRI may add valuable information for the optimal treatment selection

Continuous professional development: elevating thoracic oncology education in Europe

The @EuroRespSoc launches a new thoracic oncology continuous professional development programme http://bit.ly/31ShuTp